GaldermaAnnouncesU.S.FDAAcceptanceofRelabotulinumtoxinABiologicsLicenseApplicationResubmission
===2026/2/3 10:03:21===
and only ready-to-use liquid neuromodulator manufactured with PEARL™Technology, which is designed to preserve molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for glabellar lines and lateral canthal lines, giving patients a natural, revitalized look in a refined and well-tolerated formulation.1-5RelabotulinumtoxinA is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose/volume every time.6,7It was entirely created and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. RelabotulinumtoxinA has received a marketing authorization in numerous markets and is an investigational drug product in the U.S. Authorization conditions may vary internationally.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We
=*=*=*=*=*=
当前为第4/7页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页